过氧化物酶体增殖物激活受体激动剂和通过DNA修复逆转血管变性,迈向药物诱导再生医学的一步。

IF 1.3 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS Cardiovascular Endocrinology & Metabolism Pub Date : 2020-06-16 eCollection Date: 2020-12-01 DOI:10.1097/XCE.0000000000000217
Peter Afdal, Habiba-Allah Ismail, Mirette Ashraf, Nada Hafez, Nardine Nasry, Nouran Hafez, Nourhan Youssef, Nourhan Samy, Rana Saeed, Antoine Fakhry AbdelMassih
{"title":"过氧化物酶体增殖物激活受体激动剂和通过DNA修复逆转血管变性,迈向药物诱导再生医学的一步。","authors":"Peter Afdal, Habiba-Allah Ismail, Mirette Ashraf, Nada Hafez, Nardine Nasry, Nouran Hafez, Nourhan Youssef, Nourhan Samy, Rana Saeed, Antoine Fakhry AbdelMassih","doi":"10.1097/XCE.0000000000000217","DOIUrl":null,"url":null,"abstract":"<p><p>Endothelial dysfunction with subsequent degeneration and vasoocclusive remodeling is the hallmark of many cardiovascular disorders including pulmonary vascular disease (PVD). To date, the available treatments slows disease progression but does not prevent deterioration. Reversing such pathologies would spare many patients risky surgeries and long waiting lists for a possible organ donor. Peroxisome proliferator-activated receptor agonists were first introduced as sole insulin sensitizers, however, there is increasing body of evidence that they have different actions on DNA which might help reverse vascular degeneration. This effect appears to be mainly achieved through enhancement of DNA damage responses (DDR). The aforementioned effect could offer new insights about repurposing drugs for achieving organ or tissue regeneration, an understudied field named drug-induced regenerative medicine.</p>","PeriodicalId":43231,"journal":{"name":"Cardiovascular Endocrinology & Metabolism","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2020-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673771/pdf/xce-9-128.pdf","citationCount":"0","resultStr":"{\"title\":\"Peroxisome proliferator-activated receptor agonists and reversal of vascular degeneration through DNA repair, a step toward drug-induced regenerative medicine.\",\"authors\":\"Peter Afdal, Habiba-Allah Ismail, Mirette Ashraf, Nada Hafez, Nardine Nasry, Nouran Hafez, Nourhan Youssef, Nourhan Samy, Rana Saeed, Antoine Fakhry AbdelMassih\",\"doi\":\"10.1097/XCE.0000000000000217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Endothelial dysfunction with subsequent degeneration and vasoocclusive remodeling is the hallmark of many cardiovascular disorders including pulmonary vascular disease (PVD). To date, the available treatments slows disease progression but does not prevent deterioration. Reversing such pathologies would spare many patients risky surgeries and long waiting lists for a possible organ donor. Peroxisome proliferator-activated receptor agonists were first introduced as sole insulin sensitizers, however, there is increasing body of evidence that they have different actions on DNA which might help reverse vascular degeneration. This effect appears to be mainly achieved through enhancement of DNA damage responses (DDR). The aforementioned effect could offer new insights about repurposing drugs for achieving organ or tissue regeneration, an understudied field named drug-induced regenerative medicine.</p>\",\"PeriodicalId\":43231,\"journal\":{\"name\":\"Cardiovascular Endocrinology & Metabolism\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2020-06-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7673771/pdf/xce-9-128.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cardiovascular Endocrinology & Metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1097/XCE.0000000000000217\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2020/12/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiovascular Endocrinology & Metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1097/XCE.0000000000000217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2020/12/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

内皮功能障碍伴退变和血管闭塞性重构是包括肺血管疾病(PVD)在内的许多心血管疾病的标志。迄今为止,可用的治疗方法减缓了疾病的进展,但不能防止病情恶化。扭转这些病症将使许多患者免去高风险的手术和等待可能的器官捐赠者的漫长等待名单。过氧化物酶体增殖物激活受体激动剂最初是作为唯一的胰岛素增敏剂引入的,然而,越来越多的证据表明它们对DNA有不同的作用,可能有助于逆转血管变性。这种效应似乎主要是通过增强DNA损伤反应(DDR)来实现的。上述效应可以为重新利用药物来实现器官或组织再生提供新的见解,这是一个尚未得到充分研究的领域,名为药物诱导再生医学。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Peroxisome proliferator-activated receptor agonists and reversal of vascular degeneration through DNA repair, a step toward drug-induced regenerative medicine.

Endothelial dysfunction with subsequent degeneration and vasoocclusive remodeling is the hallmark of many cardiovascular disorders including pulmonary vascular disease (PVD). To date, the available treatments slows disease progression but does not prevent deterioration. Reversing such pathologies would spare many patients risky surgeries and long waiting lists for a possible organ donor. Peroxisome proliferator-activated receptor agonists were first introduced as sole insulin sensitizers, however, there is increasing body of evidence that they have different actions on DNA which might help reverse vascular degeneration. This effect appears to be mainly achieved through enhancement of DNA damage responses (DDR). The aforementioned effect could offer new insights about repurposing drugs for achieving organ or tissue regeneration, an understudied field named drug-induced regenerative medicine.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Cardiovascular Endocrinology & Metabolism
Cardiovascular Endocrinology & Metabolism CARDIAC & CARDIOVASCULAR SYSTEMS-
CiteScore
5.60
自引率
0.00%
发文量
24
期刊最新文献
Efficacy and safety of double-dose statin monotherapy versus moderate-intensity statin combined with ezetimibe dual therapy in diabetic patients: a systematic review and meta-analysis of randomized controlled trials. Development of acute kidney injury following repair of Stanford type A aortic dissection is associated with increased mortality and complications: a systematic review, meta-analysis, and meta-regression analysis. The link between the risk of cardiovascular diseases and the intake of different types of dietary carbohydrates in Iranian adults. The lifetime healthcare costs of female obesity: modeling of England data and the costs of current pharmacotherapy. The evolving role of GLP-1 agonists in ischemic stroke prevention in diabetic patients.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1